Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

Status Recruiting

Clinical Trial Summary

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

Clinical Trial Description

For patients with lung injury caused by major infectious diseases, conventional antiviral and anti-inflammatory treatments may not effectively improve lung function in the short term and may increase the risk of secondary infections. Therefore, in the clinical management of viral pneumonia, it is necessary to consider the lung tissue damage caused by acute viral replication and systemic immune stress, while also focusing on the subsequent lung functional impairment due to virus clearance-induced pulmonary fibrosis. Studies have shown that after peripheral intravenous administration of mesenchymal stem cells (MSCs), approximately 50% to 60% of the cells remain in the lung tissue within 1 hour, decreasing to around 30% after 3 hours. After 48 hours, MSCs tend to aggregate in the liver and spleen, and cell retention can still be detected 10 days later. MSCs aggregation in the lung tissue can secrete cell trophic factors such as keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF), promoting the regeneration of type II alveolar epithelial cells, improving the pulmonary microenvironment, and facilitating the repair of the alveolar epithelial barrier after ARDS injury.This study is intended to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06416709
Study type	Interventional
Source	Cell Energy Life Sciences Group Co. LTD
Contact	Zhe Xu, Dr
Phone	86 150 0111 1836
Email	xuzhe302@139.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	May 10, 2023
Completion date	May 10, 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05054270` - Efficacy of Lung Ultrasound in Monitoring Fluid Resuscitation in Chest Trauma Patients
Not yet recruiting	`NCT04470297` - Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19	Phase 2
Not yet recruiting	`NCT01184313` - Acute Lung Injury After Aortic Valve Surgery	N/A
Not yet recruiting	`NCT06296173` - Open Lung Protective Extubation Following General Anesthesia	N/A
Not yet recruiting	`NCT03661502` - Effect of Variable Volume Ventilation on Lung Compliance	N/A
Recruiting	`NCT04296071` - Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
Completed	`NCT04645316` - The Effect of Sevoflurane and Desflurane on Clara Cell Protein on the Lung	N/A
Recruiting	`NCT02299921` - Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure
Recruiting	`NCT05559970` - Inhalational Sedation and Mechanical Power	N/A
Completed	`NCT03581006` - Food Intake REstriction for Health OUtcome Support and Education (FIREHOUSE) Trial
Recruiting	`NCT05228717` - Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
Recruiting	`NCT04372953` - Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial).	N/A
Not yet recruiting	`NCT05363085` - The Cerebral-Respiratory Interaction in Controlled Mechanically Ventilated Neurosurgical Patients. (The CeRes-CMV Study)
Recruiting	`NCT02444858` - Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury	Phase 1/Phase 2
Completed	`NCT03924206` - Hazardous Surgical Smoke: Risk Assessment and Evaluation of a New Smoke Extractor System in the Surgical Unit
Withdrawn	`NCT01939067` - Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP	Phase 1
Recruiting	`NCT05401474` - Individualization Flow in Patients Treated With High Flow Nasal Therapy (iFLOW)	N/A
Completed	`NCT03437499` - Adrenomedullin Changes After Sustained Inflation or Positive Pressure Ventilation at Birth	N/A
Not yet recruiting	`NCT05381415` - Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD
Recruiting	`NCT04989439` - Comparison of Computertomography Scan, Electrical Impedance Tomography, and Ultrasound of the Lung in Infants